Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA) had its price objective boosted by Leerink Partners from $27.00 to $29.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners’ price target suggests a potential upside of 110.22% from the company’s previous close.

Several other analysts have also commented on the stock. Oppenheimer set a $27.00 price objective on shares of Intellia Therapeutics in a report on Friday, November 7th. Robert W. Baird set a $7.00 price target on Intellia Therapeutics in a research note on Tuesday, January 27th. Evercore set a $8.00 price objective on Intellia Therapeutics and gave the company an “in-line” rating in a research report on Tuesday, November 11th. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 target price on shares of Intellia Therapeutics in a research report on Friday. Finally, Citizens Jmp increased their price target on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.43.

Intellia Therapeutics Price Performance

NASDAQ:NTLA traded down $1.65 during trading hours on Tuesday, hitting $13.80. The company had a trading volume of 3,372,937 shares, compared to its average volume of 5,340,344. The company has a market capitalization of $1.63 billion, a PE ratio of -3.60 and a beta of 2.09. The stock has a 50-day moving average price of $12.01 and a 200 day moving average price of $13.08. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period in the prior year, the business earned ($1.27) EPS. Analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. AQR Capital Management LLC lifted its holdings in Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after acquiring an additional 55,118 shares during the period. Woodline Partners LP purchased a new stake in shares of Intellia Therapeutics during the 1st quarter valued at about $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after purchasing an additional 38,521 shares during the period. Atria Investments Inc bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth approximately $96,000. Finally, Intellectus Partners LLC boosted its holdings in shares of Intellia Therapeutics by 3.8% in the second quarter. Intellectus Partners LLC now owns 85,975 shares of the company’s stock worth $806,000 after buying an additional 3,150 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical hold on the MAGNITUDE Phase 3 IND for nexiguran ziclumeran (nex‑z) in transthyretin amyloidosis with cardiomyopathy (ATTR‑CM) — removes a major regulatory overhang and permits the late‑stage trial to proceed, which is the primary near‑term clinical catalyst for the stock. Read More.
• Positive Sentiment: Market reacted to the FDA action with a price uptick (reports noted a ~4.8% intraday rise), signaling investor relief and renewed focus on trial execution and timelines. Read More.
• Positive Sentiment: Multiple analyst upgrades/target raises — HC Wainwright raised its target to $30 (buy), Citizens JMP to $28 (market outperform), William Blair upgraded to outperform, and other firms reiterated buy ratings. These broker actions increase attention and imply significant upside vs. current levels. Read More. and Read More.
• Neutral Sentiment: Intellia presented four posters at AAAAI including three‑year follow‑up data from a one‑time 50 mg dose of lonvoguran ziclumeran (lonvo‑z) and patient‑survey findings on treatment burden/unmet needs in hereditary angioedema (HAE). Longer‑term durability data can be positive if confirmed, while patient‑burden findings underscore market opportunity and remaining unmet needs. Read More.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.